The IdyllaTM KRAS Mutation Assay detects KRAS mutations directly from FFPE tissue sections in approx. 130 minutes with less than 2 minutes hands-on time.
The IdyllaTM KRAS Mutation Assay, performed on the Biocartis IdyllaTM System, is a sample-to-result real-time PCR assay for the qualitative detection of mutations in codons 12, 13, 59, 61, 117, 146 of the KRAS oncogene.
For Research Use Only (RUO), not for use in diagnostic procedures.
For more information on the PlexZyme and PlexPrime licenses, click here.
Specimen requirements
One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the IdyllaTM system only a minimal amount of sample is needed
- 1x 5 μm FFPE tissue section → 50-600 mm²
- 1x 10 μm FFPE tissue section → 25-300 mm²
- Neoplastic cells ≥10% - if less, macrodissection is required
The opinions and conclusions expressed in the following publications are those of the individual authors and do not necessarily reflect the views and opinions of Biocartis and/or its employees.
